‘You Have To Play On A Pretty Broad Part Of The Piano’: Fresenius Kabi On Biosimilar Commitment
Exclusive Interview With Fresenius Kabi’s Biopharma Business President, Michael Schönhofen
During a broad and wide-ranging interview, taking place in the aftermath of Fresenius Kabi’s entry into the US adalimumab biosimilar market, president of the firm’s Biopharma business, Michael Schönhofen, talks about Kabi’s ambitions in the space, and how it is positioned to be a long-term player.
